Evidence map›Paper›PMID 38684324›Full record

ArticleAnnals of the rheumatic diseases2024

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc).

Minrui Liang, Lingbiao Wang, Xiaolong Tian, Kun Wang, Xiaoyi Zhu, Linlin Huang, Qing Li, Wenjing Ye, Chen Chen, Haihua Yang and 11 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Minrui Liang *Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China mliang10@fudan.edu.cn tlying@fudan.edu.cn zhou_feng@fudan.edu.cn.ORCID http://orcid.org/0000-0002-7650-1237
Lingbiao Wang *Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Xiaolong Tian *Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kun Wang *Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Xiaoyi Zhu *Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Linlin HuangDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Qing LiShanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Wenjing YeDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Chen ChenDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Haihua YangDepartment of Respiratory and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Wanqing WuDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Xiangjun ChenDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Xiaoxia ZhuDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Yu XueDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Weiguo WanDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Yanling WuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Liwei LuDepartment of Pathology, The University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-8634-0967
Jiucun WangState Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, and Human Phenome Institute, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-2765-0620
Hejian ZouDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
Tianlei YingKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China mliang10@fudan.edu.cn tlying@fudan.edu.cn zhou_feng@fudan.edu.cn.
Feng ZhouShanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China mliang10@fudan.edu.cn tlying@fudan.edu.cn zhou_feng@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc).

methodsWe implemented this strategy by conducting immunoprecipitation (IP) following on-bead digestion with the sera of patients with SSc or healthy donors, using antigen pools derived from cell lysates. The enriched antigen-antibody complex was proceeded with mass spectrometry (MS)-based quantitative proteomics and over-represented by bioinformatics analysis. The candidate antibodies were then orthogonally validated in two independent groups of patients with SSc. Mice were immunised with the target antigen, which was subsequently evaluated by histological examination and RNA sequencing.

resultsThe IP-MS analysis, followed by validation in patients with SSc, revealed a significant elevation in anti-PRMT5 antibodies among patients with SSc. These antibodies exhibited robust diagnostic accuracy in distinguishing SSc from healthy controls and other autoimmune conditions, including systemic lupus erythematosus and Sjögren's syndrome, with an area under the curve ranging from 0.900 to 0.988. The elevation of anti-PRMT5 antibodies was verified in a subsequent independent group with SSc using an additional method, microarray. Notably, 31.11% of patients with SSc exhibited seropositivity for anti-PRMT5 antibodies. Furthermore, the titres of anti-PRMT5 antibodies demonstrated a correlation with the progression or regression trajectory in SSc. PRMT5 immunisation displayed significant inflammation and fibrosis in both the skin and lungs of mice. This was concomitant with the upregulation of multiple proinflammatory and profibrotic pathways, thereby underscoring a potentially pivotal role of anti-PRMT5 antibodies in SSc.

conclusionsThis study has identified anti-PRMT5 antibodies as a novel biomarker for SSc.

Indexed as

AutoantibodiesProtein-Arginine N-MethyltransferasesScleroderma, SystemicAnimalsBiomarkersFibrosisHumansMicePulmonary FibrosisSkin DiseasesAutoantibodiesBiomarkersPRMT5 protein, humanProtein-Arginine N-MethyltransferasesAutoantibodiesAutoimmune DiseasesScleroderma, Systemic

Identifiers

PMID38684324
PMCPMC11420721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.